

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM632041

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
CRG Partners III L.P.		03/12/2021	Limited Partnership: DELAWARE
CRG Partners III - Parallel Fund "A" L.P.		03/12/2021	Limited Partnership: DELAWARE
CRG Partners III (CAYMAN ) L.P.		03/12/2021	Limited Partnership: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	DECIPHER BIOSCIENCES, INC.		
<b>Street Address:</b>	10355 Science Center Drive, Suite 240		
<b>City:</b>	San Diego		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	92121		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 10</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4618847	INFORMATION FOR LIFE	
<b>Registration Number:</b>	4610916		
<b>Registration Number:</b>	4565463	UROSKETCH 3D	
<b>Registration Number:</b>	4441544	DECIPHER	
<b>Registration Number:</b>	4426227	DECIPHER	
<b>Serial Number:</b>	86627358	DECIPHER GRID	
<b>Serial Number:</b>	86627457	GRID	
<b>Serial Number:</b>	85978205	DECIPHER	
<b>Serial Number:</b>	85875380		
<b>Serial Number:</b>	85913957	UROSKETCH 3D	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	7043311159		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	7043311000		

OP \$265.00 4618847

**Email:** iplaw@mvalaw.com, jansnider@mvalaw.com  
**Correspondent Name:** MOORE & VAN ALLEN PLLC  
**Address Line 1:** 100 NORTH TRYON STREET  
**Address Line 2:** SUITE 4700  
**Address Line 4:** CHARLOTTE, NORTH CAROLINA 28202

**NAME OF SUBMITTER:** JAMES VAN CLEAVE GAMBRELL

**SIGNATURE:** /James Van Cleave Gambrell/

**DATE SIGNED:** 03/15/2021

**Total Attachments: 8**

source=Executed IP Release - Decipher#page1.tif  
source=Executed IP Release - Decipher#page2.tif  
source=Executed IP Release - Decipher#page3.tif  
source=Executed IP Release - Decipher#page4.tif  
source=Executed IP Release - Decipher#page5.tif  
source=Executed IP Release - Decipher#page6.tif  
source=Executed IP Release - Decipher#page7.tif  
source=Executed IP Release - Decipher#page8.tif

## TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT

This TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT dated as of March \_\_, 2021 (this "Release"), is made by CRG PARTNERS III L.P., CRG PARTNERS III – Parallel Fund "A" L.P. and CRG PARTNERS III (Cayman) L.P. (together, the "Lenders" and each, a "Lender") and CRG Partners III L.P., as Administrative Agent for the Secured Parties ("Administrative Agent" and, together with the Lenders, the "Secured Parties" and each, a "Secured Party"); and DECIPHER BIOSCIENCES, INC., a Delaware corporation (formerly known as GenomeDx Inc., which is the continued and domesticated successor in interest of GenomeDx Biosciences Inc., a British Columbia corporation ("Company").

**WHEREAS**, the Company, certain subsidiaries of the Company named therein as guarantors, and the Secured Parties are parties to that certain Term Loan Agreement, dated September 23, 2015 (as amended, modified, renewed or extended from time to time, the "Loan Agreement");

**WHEREAS**, the Company and the Secured Parties are parties to that certain General Security Agreement, dated September 23, 2015 (as amended, supplemented or otherwise modified from time to time, the "General Security Agreement"), pursuant to which the Company granted to the Administrative Agent (for its own benefit and for the ratable benefit of the other Secured Parties), a security interest in certain of its assets (as more fully described therein);

**WHEREAS**, pursuant to the General Security Agreement, the Company entered into that certain Intellectual Property Security Agreement, dated September 23, 2015 (as amended, restated, supplemented or otherwise modified from time to time, the "IP Security Agreement") pursuant to which the Company granted to the Administrative Agent certain security interests provided to secure the Secured Obligations set forth in the IP Security Agreement;

**WHEREAS**, the IP Security Agreement was recorded against at the United States Patent and Trademark Office ("USPTO") for certain trademarks and trademark applications on September 23, 2015, at Reel 005629, Frame 0227.; and for certain patents and patent applications on September 23, 2015, at Reel 036639, Frame 0071.

**NOW THEREFORE**, in consideration of the mutual promises and undertakings set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and with the intention of being legally bound hereby, Administrative Agent, on behalf of the Secured Parties, and Company agree as follows:

**SECTION 1. Defined Terms.** All capitalized terms used herein but not otherwise defined herein have the meanings given to them in the IP Security Agreement or the General Security Agreement.

**SECTION 2. Termination and Release.** Administrative Agent, on behalf of the Secured Parties, without representation, warranty, or recourse, hereby:

- (a) terminates, cancels, discharges, and releases the security interest in all of the Company's right, title and interest in, to and under the following property (the "Collateral")
  - (i) all copyrights, whether statutory or common law, registered or unregistered, domestic or foreign, including the Company's registered copyrights and copyright registrations (including the registered copyrights and copyright registrations listed in Schedule 1), all of the Company's applications for copyright registrations (including the applications for copyright registrations listed in Schedule 1), and all of the Company's unregistered copyrights, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses, together

with all renewals and extensions of any copyrights, the right to recover for all past, present, and future infringements of any copyrights, and all computer programs, computer databases, computer program flow diagrams, source codes, object codes and all tangible property embodying or incorporating any copyrights, and all other rights of every kind whatsoever accruing thereunder or pertaining thereto;

(ii) all patents and patent applications, domestic or foreign, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses (including such patents and patent applications as described in Schedule 1), all rights to sue for past, present or future infringement thereof, all rights arising therefrom and pertaining thereto and all reissues, divisions, continuations, renewals, extensions and continuations-in-part thereof;

(iii) all state (including common law), federal and foreign trademarks, service marks and trade names, and applications for registration of such trademarks, service marks and trade names, all licenses relating to any of the foregoing and all income and royalties with respect to any licenses (including such marks, names and applications as described in Schedule 1), whether registered or unregistered and wherever registered, all rights to sue for past, present or future infringement or unconsented use thereof, all rights arising therefrom and pertaining thereto and all reissues, extensions and renewals thereof;

(iv) all trade secrets, trade dress, trade styles, logos, other source of business identifiers, mask-works, mask-work registrations, mask-work applications, software, confidential and proprietary information, customer lists, license rights, advertising materials, operating manuals, methods, processes, know-how, algorithms, formulae, databases, quality control procedures, product, service and technical specifications, operating, production and quality control manuals, sales literature, drawings, specifications, blue prints, descriptions, inventions, name plates, catalogs, internet websites, and internet domain names and associated URL addresses;

(v) the entire goodwill of or associated with the businesses now or hereafter conducted by the Company connected with and symbolized by any of the aforementioned properties and assets;

(vi) all commercial tort claims associated with or arising out of any of the aforementioned properties and assets;

(vii) all accounts, all intangible intellectual or other similar property and other general intangibles associated with or arising out of any of the aforementioned properties and assets and not otherwise described above, including all license payments and payments under insurance (whether or not the Agent or any of the other Secured Parties is the loss payee thereof) or any indemnity, warranty or guaranty payable by reason of loss or damage to or otherwise with respect to the foregoing Collateral; and

(viii) all products, proceeds and supporting obligations of or with respect to any and all of the foregoing Collateral; and

(b) authorizes the recordation of this Release with the USPTO at Company's expense.

**SECTION 3. Governing Law.** This Release and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; *provided that* Section 5-1401 of the New York General Obligations Law shall apply.

**IN WITNESS WHEREOF**, the Administrative Agent has caused this Termination and Release of Security Interest in Intellectual Property to be duly executed as of the day and year first above written.

**SECURED PARTIES:**

**CRG PARTNERS III L.P.**, in its  
capacity as Lender and as Administrative Agent

By CRG PARTNERS III GP L.P., its General Partner

By CRG PARTNERS III GP LLC, its  
General Partner

By: Andrei Dorenbaum  
Name: Andrei Dorenbaum  
Title: Authorized Signatory

**CRG PARTNERS III – PARALLEL FUND “A” L.P.**,

By CRG PARTNERS III – PARALLEL FUND “A”  
GP L.P., its General Partner

By CRG PARTNERS III – PARALLEL FUND  
“A” GP LLC, its General Partner

By: Andrei Dorenbaum  
Name: Andrei Dorenbaum  
Title: Authorized Signatory

**CRG PARTNERS III (CAYMAN) L.P.**,

By CRG PARTNERS III (CAYMAN) GP L.P.,  
its General Partner

By CRG PARTNERS III (CAYMAN) GP LLC,  
its General Partner


By: Andrei Dorenbaum  
Name: Andrei Dorenbaum  
Title: Authorized Signatory

[Signature Page 1 to Termination and Release of Intellectual Property Security Agreement]

ACCEPTED AND AGREED  
as of the date first above written

**Company:**

**DECIPHER BIOSCIENCES, INC.** (formerly known as  
GenomeDx Inc., which is the continued and domesticated  
successor in interest of GenomeDx Biosciences Inc.

DocuSigned by:  
  
By \_\_\_\_\_  
Name: Brent Vetter  
Title: Chief Financial Officer

*[Signature Page 2 to Termination and Release of Intellectual Property Security Agreement]*

**SCHEDULE 1**  
**to the Termination and Release of Intellectual Property Security Agreement**

**PATENTS**

U.S. Issued Patents of the Company

<b>Company*</b>	<b>Jurisdiction</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Inventor</b>	<b>Title</b>
GENOMEDX BIOSCIENCES, INC.	US	9,074,258	7/7/2015	Elai Davicioni	Compositions and Methods for Classifying Thyroid Nodule Disease

\* Decipher Biosciences, Inc. is the continued and domesticated successor in interest of GenomEdx Biosciences Inc.

Pending U.S. Issued Patent Applications of the Company

<b>Company*</b>	<b>Jurisdiction</b>	<b>Serial No.</b>	<b>Filing Date</b>	<b>Inventor</b>	<b>Title</b>
GENOMEDX BIOSCIENCES, INC.	US	12/994,408	5/28/2009	Elai Davicioni	Systems and Methods for Expression- Based Discrimination of Distinct Clinical Disease States in Prostate Cancer
GENOMEDX BIOSCIENCES, INC.	US	14/365,085	12/13/2012	Elai Davicioni	Cancer Diagnostics Using Non- Coding Transcripts
GENOMEDX BIOSCIENCES, INC.	US	13/968,838	8/16/2013	Christine Buerki	Cancer Diagnostics using biomarkers
GENOMEDX BIOSCIENCES, INC.	PCT	PCT/US2014/23693	3/11/2014	Elai Davicioni	Cancer biomarkers and classifiers and uses thereof

<b>Company*</b>	<b>Jurisdiction</b>	<b>Serial No.</b>	<b>Filing Date</b>	<b>Inventor</b>	<b>Title</b>
GENOMEDX BIOSCIENCES, INC.	US	14/772,348	9/2/2015	Elai Davicioni, Nicholas George Erho, and Lucia Lam	CANCER BIOMARKERS AND CLASSIFIERS AND USES THEREOF
GENOMEDX BIOSCIENCES, INC.	PCT	PCT/CA2014/000787	11/4/2014	Elai Davicioni	Cancer biomarkers and classifiers and uses thereof
GENOMEDX BIOSCIENCES, INC.	US	13/258,429	4/29/2010	Elai Davicioni	Systems and methods for expression based classification of thyroid tissue
GENOMEDX BIOSCIENCES, INC.	US	14/020,183	9/6/2013	Elai Davicioni	Thyroid cancer diagnostics
GENOMEDX BIOSCIENCES, INC.	US	14/727,801	6/1/2015	Elai Davicioni	Compositions and Methods for Classifying Thyroid Nodule Disease
GENOMEDX BIOSCIENCES, INC.	US	62/216,196	9/9/2015		Molecular Subtyping, Prognosis and Treatment of Prostate Cancer


\* Decipher Biosciences, Inc. is the continued and domesticated successor in interest of GenomeDx Biosciences Inc.

Licenses of Company Related to Issued Patents and Pending Patent Applications

- Patent and Know How License Agreement dated February 1, 2013, between Mayo Foundation for Medical Education and Research and GenomeDx Biosciences Inc.
- License Agreement dated as of January 22, 2013 between Regents of the University of Michigan and GenomeDx Biosciences Inc.
- Technology License Agreement dated as of September 24, 2013, between Veracyte Inc. and GenomeDx Biosciences Inc.




**TRADEMARKS**  
U.S. Registered Trademarks of the Company

Company*	Jurisdiction	Registration No.	Registration Date	Filing Date	Registered Owner*	Mark
GENOMEDX BIOSCIENCES, INC.	US	4618847	10/7/2014	1/27/2014	GENOMEDX BIOSCIENCES, INC.	INFORMATION FOR LIFE
GENOMEDX BIOSCIENCES, INC.	US	4610916	9/23/2014	3/13/2013	GENOMEDX BIOSCIENCES, INC.	
GENOMEDX BIOSCIENCES, INC.	US	4565463	7/8/2014	4/24/2013	GENOMEDX BIOSCIENCES, INC.	UROSKECH 3D
GENOMEDX BIOSCIENCES, INC.	US	4441544	11/26/2013	4/11/2012	GENOMEDX BIOSCIENCES, INC.	DECIPHER
GENOMEDX BIOSCIENCES, INC.	US	4426227	10/29/2013	4/11/2012	GENOMEDX BIOSCIENCES, INC.	DECIPHER

\* Decipher Biosciences, Inc. is the continued and domesticated successor in interest of GenomeDx Biosciences Inc.

Pending U.S. Trademark Applications of the Company

Company*	Jurisdiction	Application No.	Filing Date	Applicant*	Mark
GENOMEDX BIOSCIENCES, INC.	US	86/627,358	05/12/2015	GENOMEDX BIOSCIENCES, INC.	DECIPHER GRID
GENOMEDX BIOSCIENCES, INC.	US	86/627,457	05/12/2015	GENOMEDX BIOSCIENCES, INC.	GRID
GENOMEDX BIOSCIENCES, INC.	US	85/978,205	04/11/2012	GENOMEDX BIOSCIENCES, INC.	DECIPHER
GENOMEDX BIOSCIENCES, INC.	US	85/875,380	03/13/2013	GENOMEDX BIOSCIENCES, INC.	
GENOMEDX BIOSCIENCES, INC.	US	85/913,957	04/24/2013	GENOMEDX BIOSCIENCES, INC.	UROSKECH 3D

\* Decipher Biosciences, Inc. is the continued and domesticated successor in interest of GenomeDx Biosciences Inc.

Licenses of the Company Related to Registered Trademarks and Pending Trademark Applications

**None.**

## **COPYRIGHTS**

U.S. Registered Copyrights of the Company

**None.**

Pending U.S. Copyright Applications of the Company

**None.**

Licenses of the Company Related to Registered Copyrights and Copyright Applications

**None.**

Schedule 1-4

CHAR2\2388520v3

**RECORDED: 03/15/2021**

**TRADEMARK  
REEL: 007221 FRAME: 0429**